vs
EverCommerce Inc.（EVCM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
EverCommerce Inc.的季度营收约是再鼎医药的1.2倍（$151.2M vs $127.1M），再鼎医药同比增速更快（17.1% vs 5.2%），EverCommerce Inc.自由现金流更多（$21.0M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 4.7%）
EverCommerce Inc.是面向服务类中小企业的领先集成SaaS解决方案提供商，核心市场覆盖北美及部分全球区域，产品线包含业务管理、支付处理、客户互动、营销工具等，服务家庭服务、健康康养、健身等多个细分领域。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
EVCM vs ZLAB — 直观对比
营收规模更大
EVCM
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出11.9%
5.2%
自由现金流更多
EVCM
多$47.7M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.2M | $127.1M |
| 净利润 | $6.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 8.8% | -54.6% |
| 净利率 | 4.0% | — |
| 营收同比 | 5.2% | 17.1% |
| 净利润同比 | 149.4% | — |
| 每股收益（稀释后） | $0.04 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EVCMZLAB
| Q4 25 | $151.2M | $127.1M | ||
| Q3 25 | $147.5M | $115.4M | ||
| Q2 25 | $148.0M | $109.1M | ||
| Q1 25 | $142.3M | $105.7M | ||
| Q4 24 | $143.7M | $108.5M | ||
| Q3 24 | $140.1M | $101.8M | ||
| Q2 24 | $140.5M | $100.1M | ||
| Q1 24 | $137.9M | $87.1M |
净利润EVCMZLAB
| Q4 25 | $6.0M | — | ||
| Q3 25 | $11.1M | $-36.0M | ||
| Q2 25 | $8.2M | $-40.7M | ||
| Q1 25 | $-7.7M | $-48.4M | ||
| Q4 24 | $-12.2M | — | ||
| Q3 24 | $-9.2M | $-41.7M | ||
| Q2 24 | $-3.4M | $-80.3M | ||
| Q1 24 | $-16.3M | $-53.5M |
毛利率EVCMZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率EVCMZLAB
| Q4 25 | 8.8% | -54.6% | ||
| Q3 25 | 10.8% | -42.3% | ||
| Q2 25 | 10.7% | -50.3% | ||
| Q1 25 | 10.0% | -53.3% | ||
| Q4 24 | 8.8% | -62.6% | ||
| Q3 24 | 7.2% | -66.6% | ||
| Q2 24 | 5.5% | -76.0% | ||
| Q1 24 | -3.1% | -80.7% |
净利率EVCMZLAB
| Q4 25 | 4.0% | — | ||
| Q3 25 | 7.5% | -31.2% | ||
| Q2 25 | 5.5% | -37.3% | ||
| Q1 25 | -5.4% | -45.8% | ||
| Q4 24 | -8.5% | — | ||
| Q3 24 | -6.5% | -40.9% | ||
| Q2 24 | -2.4% | -80.2% | ||
| Q1 24 | -11.8% | -61.4% |
每股收益（稀释后）EVCMZLAB
| Q4 25 | $0.04 | $-0.05 | ||
| Q3 25 | $0.06 | $-0.03 | ||
| Q2 25 | $0.04 | $-0.04 | ||
| Q1 25 | $-0.04 | $-0.04 | ||
| Q4 24 | $-0.06 | $-0.09 | ||
| Q3 24 | $-0.05 | $-0.04 | ||
| Q2 24 | $-0.02 | $-0.08 | ||
| Q1 24 | $-0.09 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.7M | $689.6M |
| 总债务越低越好 | $523.4M | — |
| 股东权益账面价值 | $716.9M | $715.5M |
| 总资产 | $1.4B | $1.2B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
现金及短期投资EVCMZLAB
| Q4 25 | $129.7M | $689.6M | ||
| Q3 25 | $106.9M | $717.2M | ||
| Q2 25 | $151.1M | $732.2M | ||
| Q1 25 | $148.4M | $757.3M | ||
| Q4 24 | $135.8M | $779.7M | ||
| Q3 24 | $101.6M | $616.1M | ||
| Q2 24 | $86.7M | $630.0M | ||
| Q1 24 | $90.0M | $650.8M |
总债务EVCMZLAB
| Q4 25 | $523.4M | — | ||
| Q3 25 | $524.6M | — | ||
| Q2 25 | $525.8M | — | ||
| Q1 25 | $526.9M | — | ||
| Q4 24 | $527.9M | — | ||
| Q3 24 | $529.0M | — | ||
| Q2 24 | $530.1M | — | ||
| Q1 24 | $531.1M | — |
股东权益EVCMZLAB
| Q4 25 | $716.9M | $715.5M | ||
| Q3 25 | $728.5M | $759.9M | ||
| Q2 25 | $744.0M | $791.7M | ||
| Q1 25 | $739.6M | $810.8M | ||
| Q4 24 | $750.8M | $840.9M | ||
| Q3 24 | $770.7M | $667.7M | ||
| Q2 24 | $784.1M | $704.2M | ||
| Q1 24 | $800.7M | $762.2M |
总资产EVCMZLAB
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.4B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.5B | $985.3M | ||
| Q2 24 | $1.5B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
负债/权益比EVCMZLAB
| Q4 25 | 0.73× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $21.0M | $-26.7M |
| 自由现金流率自由现金流/营收 | 13.9% | -21.0% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.52× | — |
| 过去12个月自由现金流最近4个季度 | $109.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流EVCMZLAB
| Q4 25 | $21.3M | $-26.0M | ||
| Q3 25 | $32.5M | $-32.0M | ||
| Q2 25 | $27.0M | $-31.0M | ||
| Q1 25 | $30.7M | $-61.7M | ||
| Q4 24 | $48.4M | $-55.8M | ||
| Q3 24 | $27.5M | $-26.8M | ||
| Q2 24 | $23.9M | $-42.2M | ||
| Q1 24 | $13.3M | $-90.1M |
自由现金流EVCMZLAB
| Q4 25 | $21.0M | $-26.7M | ||
| Q3 25 | $31.6M | $-35.0M | ||
| Q2 25 | $26.5M | $-33.9M | ||
| Q1 25 | $30.2M | $-63.2M | ||
| Q4 24 | $48.2M | $-58.4M | ||
| Q3 24 | $27.4M | $-28.2M | ||
| Q2 24 | $23.3M | $-42.9M | ||
| Q1 24 | $12.9M | $-91.1M |
自由现金流率EVCMZLAB
| Q4 25 | 13.9% | -21.0% | ||
| Q3 25 | 21.4% | -30.4% | ||
| Q2 25 | 17.9% | -31.1% | ||
| Q1 25 | 21.2% | -59.9% | ||
| Q4 24 | 33.5% | -53.8% | ||
| Q3 24 | 19.5% | -27.7% | ||
| Q2 24 | 16.6% | -42.9% | ||
| Q1 24 | 9.4% | -104.5% |
资本支出强度EVCMZLAB
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.6% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.3% | 1.5% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.5% | 0.7% | ||
| Q1 24 | 0.3% | 1.1% |
现金转化率EVCMZLAB
| Q4 25 | 3.52× | — | ||
| Q3 25 | 2.93× | — | ||
| Q2 25 | 3.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
